- Home
- ALAR vs CGTX Comparison
ALAR vs CGTX Comparison
Compare ALAR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALAR
- CGTX
- Stock Information
- Founded
- ALAR 2013
- CGTX 2007
- Country
- ALAR Israel
- CGTX United States
- Employees
- ALAR N/A
- CGTX N/A
- Industry
- ALAR Computer Software: Prepackaged Software
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- ALAR Technology
- CGTX Health Care
- Exchange
- ALAR Nasdaq
- CGTX Nasdaq
- Market Cap
- ALAR 71.4M
- CGTX 79.3M
- IPO Year
- ALAR 2018
- CGTX 2021
- Fundamental
- Price
- ALAR $10.38
- CGTX $0.43
- Analyst Decision
- ALAR Strong Buy
- CGTX Buy
- Analyst Count
- ALAR 2
- CGTX 6
- Target Price
- ALAR $25.50
- CGTX $8.00
- AVG Volume (30 Days)
- ALAR 208.3K
- CGTX 549.6K
- Earning Date
- ALAR 11-26-2024
- CGTX 10-31-2024
- Dividend Yield
- ALAR N/A
- CGTX N/A
- EPS Growth
- ALAR N/A
- CGTX N/A
- EPS
- ALAR 0.07
- CGTX N/A
- Revenue
- ALAR $31,117,000.00
- CGTX N/A
- Revenue This Year
- ALAR $22.15
- CGTX N/A
- Revenue Next Year
- ALAR $11.59
- CGTX N/A
- P/E Ratio
- ALAR $18.07
- CGTX N/A
- Revenue Growth
- ALAR 52.26
- CGTX N/A
- 52 Week Low
- ALAR $2.92
- CGTX $0.40
- 52 Week High
- ALAR $46.69
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- ALAR 36.20
- CGTX 30.88
- Support Level
- ALAR $9.76
- CGTX $0.42
- Resistance Level
- ALAR $12.80
- CGTX $0.53
- Average True Range (ATR)
- ALAR 0.83
- CGTX 0.04
- MACD
- ALAR 0.35
- CGTX 0.01
- Stochastic Oscillator
- ALAR 20.39
- CGTX 17.79
About ALAR Alarum Technologies Ltd.
Alarum Technologies Ltd is a company engaged in the information security business. The company has two Internet access segments which include Enterprise Internet Access and Consumer Internet Access. Its Enterprise Internet Access offers web data collection and a private Internet browsing platform and Consumer Internet Access provides solutions for secure and private Internet browsing. Geographically, the company has a presence in the UK Virgin Islands, Israel, Europe, APAC, MEA, Hong Kong, the USA, and others, and generates a majority of its revenue from the APAC followed by the United States.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.